<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01795612</url>
  </required_header>
  <id_info>
    <org_study_id>I12007</org_study_id>
    <nct_id>NCT01795612</nct_id>
  </id_info>
  <brief_title>Adapted Physical Activity Effect on Aerobic Function and Fatigue at Home in Patients With Breast Cancer Treated in Adjuvant or Neoadjuvant Phase</brief_title>
  <acronym>APAC</acronym>
  <official_title>Adapted Physical Activity Effect on Aerobic Function and Fatigue at Home in Patients With Breast Cancer Treated in Adjuvant or Neoadjuvant Phase</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Limoges</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Limoges</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Physical exercise has been identified as a major item of many chronic diseases and cancer&#xD;
      rehabilitation. It contributes to an improvement in the quality of life and to a decrease in&#xD;
      the current treatment side effects and mortality. Cancer in association with treatment&#xD;
      toxicity and an inactive lifestyle lead to a fall in physical capability and causes problems&#xD;
      in daily activities. The physical capacity and the tolerance for exercise fall simultaneously&#xD;
      leading to a deconditioning vicious circle which increases physical, psychological and&#xD;
      emotional symptoms of fatigue. Therefore, physical activity for health is a valid and&#xD;
      relevant way to improve quality of life and to manage cancer patient fatigue. The aim of the&#xD;
      study is the assessment of the effects of a physical activity retraining program on aerobic&#xD;
      capacity, strength and fatigue, in a breast cancer population treated by adjuvant or&#xD;
      n√©oadjuvant chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2013</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The main criterion is exercise tolerance at 12 months measured by VO2peak by incremental cardiopulmonary exercise test</measure>
    <time_frame>at 12 months</time_frame>
    <description>unit of measure:ml/kg/min</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exercise tolerance at 12 months (group A vs B)</measure>
    <time_frame>at 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">94</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>6-month ETP, during adjuvant or neoadjuvant therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>6-month ETP, after adjuvant or neoadjuvant therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>12-monthETP, during and after adjuvant or neoadjuvant treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>physical activity</intervention_name>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  females between 18 and 75 years of age;&#xD;
&#xD;
          -  signed written informed consent;&#xD;
&#xD;
          -  willing to take part in the trial and to follow the instructions;&#xD;
&#xD;
          -  breast tumour, histologically documented;&#xD;
&#xD;
          -  patients for whom a 6-treatment course of adjuvant or neoadjuvant chemotherapy&#xD;
             (3FEC100 +3 taxanes or 6 FEC) +/- radiotherapy+/- Herceptin has been scheduled;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  metastatic cancer;&#xD;
&#xD;
          -  disability preventing a proper understanding of the instructions for the trial;&#xD;
&#xD;
          -  patients who are subject to a court protection, wardship or guardianship order;&#xD;
&#xD;
          -  uncontrolled hypertension;&#xD;
&#xD;
          -  family history of sudden death in a first-degree relative;&#xD;
&#xD;
          -  unstabilised heart disease;&#xD;
&#xD;
          -  current treatment with beta-blockers;&#xD;
&#xD;
          -  chronic or acute pulmonary disease associated with dyspnoea upon moderate effort;&#xD;
&#xD;
          -  uncontrolled thyroid dysfunction;&#xD;
&#xD;
          -  uncontrolled diabetes;&#xD;
&#xD;
          -  any other serious conditions that are unstabilised,&#xD;
&#xD;
          -  disabling or in which physical exercise is contra-indicated;&#xD;
&#xD;
          -  unable to attend for follow-up throughout the duration of the study;&#xD;
&#xD;
          -  ventricular ejection fraction (VEF) &lt; 50%, pregnancy or suckling.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Hospital, Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <study_first_submitted>February 18, 2013</study_first_submitted>
  <study_first_submitted_qc>February 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2013</study_first_posted>
  <last_update_submitted>January 11, 2019</last_update_submitted>
  <last_update_submitted_qc>January 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

